GR871067B - Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor - Google Patents

Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor

Info

Publication number
GR871067B
GR871067B GR871067A GR870101067A GR871067B GR 871067 B GR871067 B GR 871067B GR 871067 A GR871067 A GR 871067A GR 870101067 A GR870101067 A GR 870101067A GR 871067 B GR871067 B GR 871067B
Authority
GR
Greece
Prior art keywords
pharmaceutical preparation
stimulating factor
colony stimulating
preparation containing
granulocyte colony
Prior art date
Application number
GR871067A
Other languages
Greek (el)
English (en)
Inventor
Minoru Machida
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of GR871067B publication Critical patent/GR871067B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GR871067A 1986-07-18 1987-07-08 Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor GR871067B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948886 1986-07-18
JP16948986 1986-07-18
JP16948786 1986-07-18
JP16948686 1986-07-18

Publications (1)

Publication Number Publication Date
GR871067B true GR871067B (en) 1987-11-19

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
GR871067A GR871067B (en) 1986-07-18 1987-07-08 Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor

Country Status (24)

Country Link
KR (1) KR930004597B1 (nl)
CN (1) CN1033738C (nl)
AT (1) AT402259B (nl)
AU (1) AU611856B2 (nl)
BE (1) BE1000253A3 (nl)
CA (1) CA1297007C (nl)
CH (1) CH671157A5 (nl)
DE (1) DE3723781C2 (nl)
DK (1) DK171308B1 (nl)
ES (1) ES2010226A6 (nl)
FR (1) FR2601591B1 (nl)
GB (1) GB2193631B (nl)
GR (1) GR871067B (nl)
HK (1) HK64893A (nl)
HU (1) HU198627B (nl)
IE (1) IE60290B1 (nl)
IL (1) IL83220A (nl)
IT (1) IT1218927B (nl)
NL (1) NL192917C (nl)
NO (1) NO171828C (nl)
PT (1) PT85343B (nl)
SE (1) SE503312C2 (nl)
SG (1) SG64393G (nl)
YU (1) YU47543B (nl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
EP0582932A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
AU749815B2 (en) * 1998-03-06 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
ATE389414T1 (de) * 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
US7163671B2 (en) * 2000-02-29 2007-01-16 Chugai Seiyaku Kabushiki Kaisha Long-term stabilized formulations
CA2337661A1 (en) 2000-02-29 2001-08-29 Pfizer Products Inc. Stabilized granulocyte colony stimulating factor
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
AU8260701A (en) 2000-09-01 2002-03-13 Chugai Pharmaceutical Co Ltd Solution preparations stabilized over long time
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Ｃｘｃｒ４拮抗薬およびその用途
WO2004075913A1 (ja) 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha タンパク質含有安定化製剤
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP2094274A4 (en) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR BONE MARROW RECOVERY
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
CN107412737A (zh) * 2010-01-19 2017-12-01 韩美科学株式会社 长效g‑csf缀合物的液体制剂
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
KR20180063881A (ko) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
JP7549530B2 (ja) * 2018-05-21 2024-09-11 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
SE451844B (sv) * 1978-03-20 1987-11-02 Morinaga Milk Industry Co Ltd Glykoprotein, forfarande for framstellning derav samt terapeutiskt medel innehallande nemnda glykoprotein
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
WO1986004587A1 (en) * 1985-02-05 1986-08-14 Cetus Corporation Purification of native colony stimulating factor-1
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤

Also Published As

Publication number Publication date
CH671157A5 (de) 1989-08-15
DE3723781C2 (de) 1999-09-02
HU198627B (en) 1989-11-28
AU7566587A (en) 1988-01-21
ES2010226A6 (es) 1989-11-01
HK64893A (en) 1993-07-16
IL83220A (en) 1993-01-31
IT8767594A0 (it) 1987-07-10
SE503312C2 (sv) 1996-05-13
CA1297007C (en) 1992-03-10
GB2193631B (en) 1990-11-21
GB8716904D0 (en) 1987-08-26
BE1000253A3 (fr) 1988-09-27
KR880001297A (ko) 1988-04-22
NO171828C (no) 1993-05-12
IL83220A0 (en) 1987-12-31
AT402259B (de) 1997-03-25
KR930004597B1 (ko) 1993-06-01
SE8702907L (sv) 1988-01-19
IE871933L (en) 1988-01-18
HUT44941A (en) 1988-05-30
CN1033738C (zh) 1997-01-08
AU611856B2 (en) 1991-06-27
DE3723781A1 (de) 1988-01-21
PT85343B (pt) 1990-04-30
NO872966L (no) 1988-01-19
DK171308B1 (da) 1996-09-02
SG64393G (en) 1993-08-06
DK368387A (da) 1988-01-19
FR2601591A1 (fr) 1988-01-22
GB2193631A (en) 1988-02-17
IE60290B1 (en) 1994-06-29
FR2601591B1 (fr) 1991-04-26
DK368387D0 (da) 1987-07-15
YU47543B (sh) 1995-10-03
PT85343A (en) 1987-08-01
NL192917B (nl) 1998-01-05
NO171828B (no) 1993-02-01
NO872966D0 (no) 1987-07-16
IT1218927B (it) 1990-04-24
YU134287A (en) 1989-06-30
NL8701640A (nl) 1988-02-16
SE8702907D0 (sv) 1987-07-17
CN87104963A (zh) 1988-02-24
NL192917C (nl) 1998-05-07
ATA177587A (de) 1996-08-15

Similar Documents

Publication Publication Date Title
GR871067B (en) Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
HUT45954A (en) Process for producing tetrahydronaphtalene- and indanederivatives and pharmaceutical compositions containing them
HUT40453A (en) Process for producing 11-beta-phenyl-gonanes and pharmaceutical compositions containing them
HUT41772A (en) Process for producing /4-substituted-piperazinyl- and -homopiperazinyl/-pyridazines and pharmaceutical compositions containing them
HUT42321A (en) Process for preparing pharmaceutical compositions
HUT47274A (en) Process for producing terciary hydroxy-alkyl-xantines and pharmaceutical compositions containing them as active components
YU15686A (en) Process for producing ceramic complex structure
HUT41790A (en) Process for producing beta-amino-purine derivatives and pharmaceutical compositions containing them
HUT49481A (en) Improved process for producing pharmaceutical compositions containing calcium-salts
HUT47278A (en) Process for producing pyrrolo-benzimidazols and pharmaceutical compositions containing them
HUT49288A (en) Process for producing nasal pharmaceutical composition
DE3660768D1 (en) Process for producing physiologically active substance
HUT46857A (en) Process for producing pharmaceutical compositions for treating bone-hurts
HUT42478A (en) Process for producing gamma-carboline derivatives and pharmaceutical compositions containing them
HUT50121A (en) Process for producing piperidinyl-derivatives and pharmaceutical compositions containing them
US4845059B1 (en) Process for producing alpha-sialon powder
HUT41035A (en) Process for producing cepheme derivatives and pharmaceutical compositions containing them
HUT41392A (en) Process for producing new imidazolyl-alkyl-guanidine derivatives and pharmaceutical compositions containing them
HUT43820A (en) Process for producing n-(-2-((-2-hydroxy-phenyl-)(-phenyl-)-methylene-aminosquare )-ethyl-)-acetamide derivatives and pharmaceutical compositions containing them
ZA875268B (en) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
HUT41762A (en) Process for producing thieno-benzo-pyranes, -thiopyranes and naphtothiophenes and pharmaceutical compositions containing them
HUT41984A (en) Process for producing pharmaceutical compositions containing 9,10-dihydro-ergot-alkaloides
HUT44524A (en) Process for producing 1,3-thiazolyl- or 1,3,4-thiadiazolyl- derivatives and pharmaceutical compositions containing them
HUT46534A (en) Process for producing pharmaceutical composition containing benzopirane-2-carboxylik acid derivative
HUT44527A (en) Process for producing new alkylene-diamine derivatives and pharmaceutical compositions containing them